Strikingly, the combination of the αEGFR-172 ADC with the anti-PD-L1 antibody completely suppressed tumor growth and led to the survival of all mice, suggesting a synergy between these two treatments (Fig. 2 A and B). This evidence concerns the gene CD274 and neoplasm.